Abstract
Introduction: Little is known about the relationship between cigarette smoking and agonist treatment in opioid-dependent pregnant patients. The objective of this study is to examine the extent to which cigarette smoking profiles differentially changed during the course of pregnancy in opioid-dependent patients receiving either double-blind methadone or buprenorphine. Patients were participants in the international, randomized controlled Maternal Opioid Treatment: Human Experimental Research (MOTHER) study. Methods: A sample of opioid-maintained pregnant patients (18-41 years old) with available smoking data who completed a multisite, double-blind, double-dummy, randomized controlled trial of methadone (n = 67) and buprenorphine (n = 57) between 2005 and 2008. Participants were compared on smoking variables based on opioid agonist treatment condition. Results: Overall, 95% of the sample reported cigarette smoking at treatment entry. Participants in the two medication conditions were similar on pretreatment characteristics including smoking rates and daily cigarette amounts. Over the course of the pregnancy, no meaningful changes in cigarette smoking were observed for either medication condition. The fitted difference in change in adjusted cigarettes per day between the two conditions was small and nonsignificant (β = -0.08, SE = 0.05, p = .132). Conclusions: Results support high rates of smoking with little change during pregnancy among opioid-dependent patients, regardless of the type of agonist medication received. These findings are consistent with evidence that suggests nicotine effects, and interactions may be similar for buprenorphine compared with methadone. The outcomes further highlight that aggressive efforts are needed to reduce/eliminate smoking in opioid-dependent pregnant women.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1297-1304 |
| Number of pages | 8 |
| Journal | Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco |
| Volume | 15 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2013 |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
Cite this
A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. / Chisolm, Margaret S; Fitzsimons, Heather; Leoutsakos, Jeannie-Marie S; Acquavita, Shauna P.; Heil, Sarah H.; Wilson-Murphy, Molly; Tuten, Michelle; Kaltenbach, Karol; Martin, Peter R.; Winklbaur, Bernadette; Jansson, Lauren M; Jones, Hendrée E.
In: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, Vol. 15, No. 7, 07.2013, p. 1297-1304.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine
AU - Chisolm, Margaret S
AU - Fitzsimons, Heather
AU - Leoutsakos, Jeannie-Marie S
AU - Acquavita, Shauna P.
AU - Heil, Sarah H.
AU - Wilson-Murphy, Molly
AU - Tuten, Michelle
AU - Kaltenbach, Karol
AU - Martin, Peter R.
AU - Winklbaur, Bernadette
AU - Jansson, Lauren M
AU - Jones, Hendrée E.
PY - 2013/7
Y1 - 2013/7
N2 - Introduction: Little is known about the relationship between cigarette smoking and agonist treatment in opioid-dependent pregnant patients. The objective of this study is to examine the extent to which cigarette smoking profiles differentially changed during the course of pregnancy in opioid-dependent patients receiving either double-blind methadone or buprenorphine. Patients were participants in the international, randomized controlled Maternal Opioid Treatment: Human Experimental Research (MOTHER) study. Methods: A sample of opioid-maintained pregnant patients (18-41 years old) with available smoking data who completed a multisite, double-blind, double-dummy, randomized controlled trial of methadone (n = 67) and buprenorphine (n = 57) between 2005 and 2008. Participants were compared on smoking variables based on opioid agonist treatment condition. Results: Overall, 95% of the sample reported cigarette smoking at treatment entry. Participants in the two medication conditions were similar on pretreatment characteristics including smoking rates and daily cigarette amounts. Over the course of the pregnancy, no meaningful changes in cigarette smoking were observed for either medication condition. The fitted difference in change in adjusted cigarettes per day between the two conditions was small and nonsignificant (β = -0.08, SE = 0.05, p = .132). Conclusions: Results support high rates of smoking with little change during pregnancy among opioid-dependent patients, regardless of the type of agonist medication received. These findings are consistent with evidence that suggests nicotine effects, and interactions may be similar for buprenorphine compared with methadone. The outcomes further highlight that aggressive efforts are needed to reduce/eliminate smoking in opioid-dependent pregnant women.
AB - Introduction: Little is known about the relationship between cigarette smoking and agonist treatment in opioid-dependent pregnant patients. The objective of this study is to examine the extent to which cigarette smoking profiles differentially changed during the course of pregnancy in opioid-dependent patients receiving either double-blind methadone or buprenorphine. Patients were participants in the international, randomized controlled Maternal Opioid Treatment: Human Experimental Research (MOTHER) study. Methods: A sample of opioid-maintained pregnant patients (18-41 years old) with available smoking data who completed a multisite, double-blind, double-dummy, randomized controlled trial of methadone (n = 67) and buprenorphine (n = 57) between 2005 and 2008. Participants were compared on smoking variables based on opioid agonist treatment condition. Results: Overall, 95% of the sample reported cigarette smoking at treatment entry. Participants in the two medication conditions were similar on pretreatment characteristics including smoking rates and daily cigarette amounts. Over the course of the pregnancy, no meaningful changes in cigarette smoking were observed for either medication condition. The fitted difference in change in adjusted cigarettes per day between the two conditions was small and nonsignificant (β = -0.08, SE = 0.05, p = .132). Conclusions: Results support high rates of smoking with little change during pregnancy among opioid-dependent patients, regardless of the type of agonist medication received. These findings are consistent with evidence that suggests nicotine effects, and interactions may be similar for buprenorphine compared with methadone. The outcomes further highlight that aggressive efforts are needed to reduce/eliminate smoking in opioid-dependent pregnant women.
UR - http://www.scopus.com/inward/record.url?scp=84879333011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879333011&partnerID=8YFLogxK
U2 - 10.1093/ntr/nts274
DO - 10.1093/ntr/nts274
M3 - Article
C2 - 23288871
AN - SCOPUS:84879333011
VL - 15
SP - 1297
EP - 1304
JO - Nicotine and Tobacco Research
JF - Nicotine and Tobacco Research
SN - 1462-2203
IS - 7
ER -